Seminars in arthritis and rheumatism最新文献

{"title":"Can we identify axial spondyloarthritis among young adults referred to non-rheumatology specialists? Results from the SHERPAS study","authors":"Benavent D ,&nbsp;Tapia M ,&nbsp;Bernabeu D ,&nbsp;Muley V ,&nbsp;Juárez M ,&nbsp;Balsa A ,&nbsp;Plasencia Ch ,&nbsp;Navarro-Compán V","doi":"10.1016/j.semarthrit.2025.152780","DOIUrl":"10.1016/j.semarthrit.2025.152780","url":null,"abstract":"<div><h3>Objective</h3><div>To determine the prevalence and features associated with axSpA diagnosis in young adults with chronic back pain (CBP) referred to specialists other than rheumatologists, and to evaluate magnetic resonance imaging (MRI) of sacroiliac joints (SIJ) in this population.</div></div><div><h3>Methods</h3><div>A prospective, observational study was conducted from July 2021 to October 2023. Adults aged 18–40 years with CBP referred for spinal MRI by non-rheumatology specialists were included. Participants completed a self-administered questionnaire assessing back pain characteristics and SpA features. The spinal MRI was extended to SIJ. Thereafter, participants were evaluated by a rheumatologist, who established the diagnosis of axSpA based on clinical evaluation and complementary tests.</div></div><div><h3>Results</h3><div>Among 268 patients enrolled, 8 (3.0 %) were diagnosed with definite axSpA, and 14 (5.2 %) suspected axSpA cases, resulting in a total of 8.2 % with definite or suspected axSpA. Buttock pain (54.5 % vs. 24.3 %; p = 0.04), improvement with NSAIDs (68.2 % vs. 36.5 %; p = 0.02), shorter symptom duration (3.5 vs. 5.1 years; p = 0.02), HLA-B27 positivity (27.3 % vs. 3.3 %; p &lt; 0.01), and elevated CRP levels (36.4 % vs. 12.2 %; p = 0.01) were associated with axSpA diagnosis. MRI findings revealed spinal degenerative lesions in most patients, and SIJ abnormalities in almost one third, being more common in patients with axSpA.</div></div><div><h3>Conclusion</h3><div>In our cohort of young adults with CBP referred to non-rheumatology specialists, approximately 8 % were diagnosed with definite or suspected axSpA. MRI spinal lesions were reported in most patients, while SIJ findings were reported in one out of three patients.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152780"},"PeriodicalIF":4.6,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144597212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refining RA-ILD screening: Diagnostic limitations and the emerging role of lung ultrasound","authors":"Horacio Matías Castro","doi":"10.1016/j.semarthrit.2025.152775","DOIUrl":"10.1016/j.semarthrit.2025.152775","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152775"},"PeriodicalIF":4.6,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144522767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discriminating capacity of the ASAS health index in patients with axial spondyloarthritis treated with ixekizumab","authors":"Uta Kiltz ,&nbsp;Anna Moltó ,&nbsp;Désirée van der Heijde ,&nbsp;Louis Bessette ,&nbsp;Annelies Boonen ,&nbsp;Rebecca Bolce ,&nbsp;Christophe Sapin ,&nbsp;Theresa Hunter Gibble ,&nbsp;Boris Janos ,&nbsp;Andris Kronbergs ,&nbsp;Khai Jing Ng ,&nbsp;Jürgen Braun","doi":"10.1016/j.semarthrit.2025.152777","DOIUrl":"10.1016/j.semarthrit.2025.152777","url":null,"abstract":"<div><h3>Objective</h3><div>To test the discriminating capacity of different thresholds of the Assessment of SpondyloArthritis international Society Health Index (ASAS HI) in placebo-controlled trials of patients with axial spondyloarthritis (axSpA), including radiographic (r-axSpA) and non-radiographic (nr-axSpA) subtypes.</div></div><div><h3>Methods</h3><div>The discriminating capacities of absolute (≥2.0–≥4.0 points) and relative (≥20%–≥50%) ASAS HI improvement thresholds were evaluated in patients with axSpA from three COAST trials (COAST-V, COAST-W, and COAST-X) of ixekizumab every 4 weeks (IXE Q4W) vs. placebo. Threshold-based response rates at Week 16 were compared between trial arms using Fisher’s exact test. Odds ratios and phi coefficients were used to evaluate how strongly each improvement threshold was associated with treatment allocation in a given trial. Missing data were handled using non-responder imputation.</div></div><div><h3>Results</h3><div>ASAS HI data were available at baseline and Week 16 for 587 patients in IXE Q4W and placebo arms. The ASAS HI ≥30% improvement threshold effectively discriminated treatment allocation in all trials; significant differences were observed between IXE Q4W and placebo in r-axSpA (COAST-V: p = 0.026; COAST-W: p = 0.023) and nr-axSpA (COAST-X: p = 0.040). Lower absolute (≥2.0–≥3.0 points) and relative (≥20%–≥30%) thresholds discriminated effectively in COAST-W, whereas higher absolute (≥3.5–≥4.0 points) and relative (≥30%–≥50%) thresholds discriminated effectively in COAST-V. In COAST-X, ≥30%, ≥40%, and ≥50% thresholds discriminated effectively. Phi coefficients were small (&lt;0.3) across all trials and thresholds.</div></div><div><h3>Conclusions</h3><div>Several ASAS HI improvement thresholds discriminated axSpA patients in treatment vs. placebo arms at Week 16. The ASAS HI ≥30% improvement threshold discriminated across all three COAST trials.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152777"},"PeriodicalIF":4.6,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144589293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the letter regarding “Validation study of the SER/SEPAR screening criteria for interstitial lung disease in early rheumatoid arthritis patients” by Martinez-Castro","authors":"Javier Narváez,&nbsp;Martí Aguilar-Coll","doi":"10.1016/j.semarthrit.2025.152776","DOIUrl":"10.1016/j.semarthrit.2025.152776","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152776"},"PeriodicalIF":4.6,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144522766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two clinical subgroups of immune checkpoint inhibitor-induced inflammatory arthritis determined by latent class analysis","authors":"Laura C. Cappelli ,&nbsp;Jamie Perin ,&nbsp;Scott Zeger ,&nbsp;Michelle Jones ,&nbsp;Clifton O. Bingham ,&nbsp;Ami A. Shah","doi":"10.1016/j.semarthrit.2025.152773","DOIUrl":"10.1016/j.semarthrit.2025.152773","url":null,"abstract":"<div><h3>Background</h3><div>Immune checkpoint inhibitors (ICI) for cancer treatment can cause inflammatory arthritis (IA). Since ICI-IA has a unique pathogenesis, applying categories of traditional IA may be of limited use.</div></div><div><h3>Methods</h3><div>Participants were ≥18 years old, treated with anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 agents, and had ICI-IA diagnosed by a rheumatologist. We clustered patients using latent class analysis (LCA) applied with phenotypic data from the baseline rheumatology visit. The Bayesian Information Criteria (BIC) was used to select the number of phenotypes. We compared demographics, cancer type and treatments, and IA clinical features and treatments between the estimated phenotypes. Finally, we explored differences in cytokine levels and the presence of shared epitope between the groups.</div></div><div><h3>Results</h3><div>Twenty variables were used to estimate latent classes. Two distinct phenotypes were indicated by the BIC; 77 patients were estimated to be the first phenotype and 49 in the second phenotype. The statistically significant features that distinguished the phenotypes included higher levels of all components of the CDAI, more stiffness, and more small and upper extremity joint involvement for phenotype 2. Patients in phenotype 2 were marginally more likely to require steroids during their course. There were no significant differences in cancer type, stage or ICI treatment between the phenotype groups. Baseline levels of VEGF-A were higher in phenotype 2.</div></div><div><h3>Conclusions</h3><div>Two separate phenotypes of ICI-IA were identified using LCA, the second having a more severe polyarthritis at baseline and involving the upper extremities. These subgroups provide an opportunity to identify corresponding biomarkers to predict disease outcomes.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152773"},"PeriodicalIF":4.6,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144321727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effectiveness and safety of rituximab in juvenile idiopathic arthritis: Hints from the ITHACA monocentric registry","authors":"Maria Rosa Pellico ,&nbsp;Marco Pandolfi ,&nbsp;Andrea Amati ,&nbsp;Claudia Iannone ,&nbsp;Sabino Germinario ,&nbsp;Stefania Costi ,&nbsp;Francesco Baldo ,&nbsp;Maurizio Gattinara ,&nbsp;Elisabetta Miserocchi ,&nbsp;Maria Gerosa ,&nbsp;Achille Marino ,&nbsp;Roberto Caporali ,&nbsp;Cecilia Beatrice Chighizola","doi":"10.1016/j.semarthrit.2025.152774","DOIUrl":"10.1016/j.semarthrit.2025.152774","url":null,"abstract":"<div><div>B cells contribute to the pathogenesis of juvenile idiopathic arthritis (JIA), suggesting a therapeutic potential for B cell depleting agent rituximab (RTX).</div><div>This retrospective study describes the effectiveness and safety of RTX in a monocentric cohort of JIA patients. Disease activity was assessed using DAS28-CRP at baseline and at each RTX infusion.</div><div>Thirty-seven JIA patients (56.8 % with polyarticular JIA) received RTX between 2008 and 2023, at a median age of 23.5 years. Most patients had a refractory disease: 45.9 % of the cohort received &gt;2 prior biologics. The median exposure time to RTX was 2.5 years, with a median number of 5 cycles per patient and a median follow-up from first infusion of 7.44 years. At 6 months, 73 % of patients responded to RTX, and 48.6 % achieved remission. At 12 months, the trend in reducing DAS28-CRP levels persisted. ACPA positivity improved remission rates although not significantly; in most cases, uveitis did not respond to RTX. Six patients (16.2 %) discontinued RTX thanks to a prolonged remission, none requiring further biologics at a follow-up of 1.4 years. Both hypogammaglobulinemia and clinically relevant infections occurred in 27 % of the cohort. Receiving &gt;4 RTX cycles predicted the development of hypogammaglobulinemia and/or infections (sensitivity 71.9 %, specificity 60.0 %).</div><div>Although the optimal patient selection strategy remains unclear, RTX might be regarded as an effective treatment for refractory cases, particularly in oligo/polyarticular JIA, with a manageable safety profile when exposure is limited to 4 cycles.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152774"},"PeriodicalIF":4.6,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144366117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging in large-vessel vasculitis: Response to Abu-Zeinah et al.","authors":"Adrián Martín-Gutiérrez ,&nbsp;Javier Loricera ,&nbsp;Santos Castañeda ,&nbsp;Ricardo Blanco ,&nbsp;Tocilizumab in Giant Cell Arteritis Spanish Collaborative Group","doi":"10.1016/j.semarthrit.2025.152772","DOIUrl":"10.1016/j.semarthrit.2025.152772","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152772"},"PeriodicalIF":4.4,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144485780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence of gout diagnosis among participants with hyperuricemia, insights from a nationwide cohort study","authors":"Shay Brikman ,&nbsp;Oriel Perets ,&nbsp;Liel Serfaty ,&nbsp;Ran Abuhasira ,&nbsp;Naomi Schlesinger ,&nbsp;Snait Ayalon ,&nbsp;Amir Bieber ,&nbsp;Nadav Rappoport","doi":"10.1016/j.semarthrit.2025.152764","DOIUrl":"10.1016/j.semarthrit.2025.152764","url":null,"abstract":"<div><h3>Objectives</h3><div>To examine the relationship between serum urate (SU) levels in hyperuricemic participants and the risk of developing gout.</div></div><div><h3>Methods</h3><div>A retrospective nationwide Israeli cohort study used the Clalit Health Insurance database of 473,124 individuals to identify adults aged 16 or older with at least two SU measurements exceeding 6.8 mg/dL between January 2007 and December 2022. Participants with a prior gout diagnosis or on gout medications were excluded. The primary outcome was a gout diagnosis, at least 90 days after the second record of hyperuricemia. Individuals were divided into four quartiles according to their second SU level. Survival analysis using Cox proportional hazards regression was conducted to evaluate the incidence of gout across SU quartiles.</div></div><div><h3>Results</h3><div>301,385 participants were defined as having hyperuricemia, of whom 15,055 (5 %) were diagnosed with gout after the index date. The mean/median of the second SU level of each quartile was 6.95/6.96 mg/dL, 7.20/7.20 mg/dL, 7.58/7.60 mg/dL, and 8.62/8.38 mg/dL, respectively. Participants with hyperuricemia from the highest SU quartile showed the steepest linear decline rate of gout-free survival (log-rank test P-value&lt;0.0001). Thirteen percent (13 %) of participants in the highest SU quartile developed gout over 10 years, also showing a steady annual incidence rate of gout of 1.3 % (in that fourth quartile).</div></div><div><h3>Conclusion</h3><div>Among participants with hyperuricemia, SU level stands out as the most important risk factor associated with significant increase in the incidence of gout.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152764"},"PeriodicalIF":4.6,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144481564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PET-guided detection of relapse in large-vessel vasculitis during tocilizumab therapy: A comment on “Relapses in giant cell arteritis treated with tocilizumab. Retrospective multicenter study of 407 patients in clinical practice”","authors":"Khalid Abu-Zeinah ,&nbsp;Kenneth J. Warrington ,&nbsp;Matthew J. Koster","doi":"10.1016/j.semarthrit.2025.152771","DOIUrl":"10.1016/j.semarthrit.2025.152771","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152771"},"PeriodicalIF":4.4,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144317854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AA amyloidosis in inflammatory joint diseases: A systematic review","authors":"Binta SAVADOGO ,&nbsp;Hanna FAHED ,&nbsp;Jérémie SELLAM ,&nbsp;Sophie GEORGIN-LAVIALLE ,&nbsp;Bruno FAUTREL ,&nbsp;Stéphane MITROVIC","doi":"10.1016/j.semarthrit.2025.152762","DOIUrl":"10.1016/j.semarthrit.2025.152762","url":null,"abstract":"<div><h3>Background</h3><div>AA amyloidosis (AAA) is a complication of chronic inflammation; the burden is expected to decrease with recent therapies. We conducted a systematic review of the incidence, prevalence, mortality and response to treatment of inflammatory joint disease (IJD)-related AAA.</div></div><div><h3>Methods</h3><div>MEDLINE, EMBASE and Cochrane library databases were searched until October 2024. Selected studies were prospective and retrospective cohorts as well as case series (≥ 10 patients) of histologically proven AAA occurring in IJD.</div></div><div><h3>Results</h3><div>From 1094 articles identified, we included 33. Substantial heterogeneity among studies was observed. Most studies (75.8 %) were published before 2010. No clear trend was identifiable in AAA incidence and mortality during the last decades. AAA prevalence rates in rheumatoid arthritis ranged from 16.7 % to 25.2 % before 2010 and decreased to 0.7 % after 2010, which suggests a potential positive role of biologic therapies. Similarly, AAA prevalence rates in ankylosing spondylitis ranged from 6.1 % to 8.5 % before 2010 and 1.1 % to 1.3 % after 2010. Immunomodulating therapies (especially biologics) seemed to improve values of AAA biomarkers, such as glomerular filtration rate and serum amyloid A level.</div></div><div><h3>Conclusions</h3><div>Our work highlights the need for more recent and comprehensive population-based epidemiological data to decipher the actual IJD-related AAA burden.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152762"},"PeriodicalIF":4.6,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144270750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}